Pieris Pharmaceuticals (PIRS) and Its Rivals Critical Review

Pieris Pharmaceuticals (NASDAQ: PIRS) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Pieris Pharmaceuticals to related companies based on the strength of its risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Analyst Recommendations

This is a breakdown of recent ratings for Pieris Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pieris Pharmaceuticals 0 0 3 0 3.00
Pieris Pharmaceuticals Competitors 839 3190 11567 230 2.71

Pieris Pharmaceuticals presently has a consensus price target of $9.00, indicating a potential upside of 48.27%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.11%. Given Pieris Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Pieris Pharmaceuticals is more favorable than its rivals.

Insider and Institutional Ownership

50.5% of Pieris Pharmaceuticals shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 4.1% of Pieris Pharmaceuticals shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Pieris Pharmaceuticals and its rivals top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Pieris Pharmaceuticals $5.83 million -$22.79 million -8.32
Pieris Pharmaceuticals Competitors $284.30 million $34.29 million 141.04

Pieris Pharmaceuticals’ rivals have higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Pieris Pharmaceuticals has a beta of -76.07, indicating that its share price is 7,707% less volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals’ rivals have a beta of 5.71, indicating that their average share price is 471% more volatile than the S&P 500.


This table compares Pieris Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Pieris Pharmaceuticals -321.83% -221.93% -42.02%
Pieris Pharmaceuticals Competitors -5,263.56% -428.00% -38.66%

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids. It is focused on developing three drug candidates, which include PRS-080, PRS-060 and PRS-300 series. Its PRS-080 is an Anticalin drug candidate targeting hepcidin. The Company’s second Anticalin drug candidate, PRS-060, binds to the IL-4 receptor alpha-chain (IL-4RA), thereby inhibiting the actions of IL-4 and IL-13, two cytokines known to be mediators in the inflammatory cascade that causes asthma and other inflammatory diseases. PRS-343 is an Anticalin-based drug candidate.

What are top analysts saying about Pieris Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pieris Pharmaceuticals Inc. and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit